loading page

Effectiveness and controversy of convalescent plasma therapy for COVID-19 patients
  • +2
  • zhanjun Shu,
  • xin Da,
  • qianqian Qian,
  • dandan Du,
  • ke Wang
zhanjun Shu
the fourth affiliated hospital of xinjiang medical university
Author Profile
xin Da
Central Hospital of Karamay
Author Profile
qianqian Qian
the eighth affiliated hospital of xinjiang medical university
Author Profile
dandan Du
xinjiang medical university
Author Profile
ke Wang
Guangdong Tuberculosis Control Center, Shipai Village, Huangpu Dadao, Tianhe District, Guangzhou City, Guangdong Province
Author Profile

Abstract

Coronavirus disease2019(COVID-19) is a pandemic with no specific therapeutic agents and substantial mortality. It is critical to find new treatments. Convalescent plasma, donated by persons who have recovered from COVID-19, is the acellular component of blood that contains antibodies, including those that specifically recognize SARS-CoV-2. Therefore, for COVID-19 patients, Convalescent plasma, could prove lifesaving, such as improving the clinical symptoms, increasing the neutralizing antibody, decreasing the viral load , reducing the death rate, with safety and without seriously ADE. Meanwhile, it is urgent to perform large sample randomized controlled trials to confirm the transfusion timing, dosage, frequency and actively prevent adverse outcomes that may occur, establishing a standard procedure for treatment from convalescent plasma collection, preservation, transport, to transfusion.

Peer review status:UNDER REVIEW

18 Nov 2020Submitted to British Journal of Pharmacology
19 Nov 2020Assigned to Editor
19 Nov 2020Submission Checks Completed
27 Nov 2020Reviewer(s) Assigned